HomeIndustriesMerck Raises Full-Year Forecast After Beating Q2 Estimate

Merck Raises Full-Year Forecast After Beating Q2 Estimate

Merck & Co decided to raise its full-year revenue forecast on Tuesday after posting better-than-expected financial results for the second quarter. Shares in the company rose by 1% in premarket trading on Tuesday morning.

Sales for Q2 were $15 billion, up from $14.6 billion during the same quarter a year ago. This comes despite a sharp decline in demand for the company’s COVID-19 therapeutic Lagevrio.

Keytruda drug sales for the quarter were $6.3 billion, outpacing the $5.9 billion forecasted by analysts. Sales for the cancer prevention drug Gardasil have surged by 47% to $2.5 billion. In contrast, sales of Lagevrio plummeted from $1.2 billion a year ago to $200 million today.

Despite positive revenue data, the company reported a quarterly adjusted loss of $5.2 billion, or $2.06 a share. This is primarily because of the $10.2 billion forked out by Merck to acquire Prometheus Biosciences. Even with this major expense, the company’s loss still beat analysts’ expectations of a $2.18 loss per share.

Merck now expects full-year sales in the range of $58.6 to $59.6 billion; up from its previous forecast of $57.7 billion to $58.9 billion.

Home Sales Plummeted in August According to Pending Data

Pending home sales for August were down 7.1% from the previous month, data from the National Association of Realtors revealed. This far outpaces the...

Stocks Fall After the Release of GDP Data

U.S. stocks declined on Thursday as investors digested the latest round of GDP data. Estimates on Thursday showed that the U.S. economy's GDP for...

Hyundai and Kia Recall Over 3 Million Vehicles Due to Fire Risk

Hyundai and Kia are in the process of recalling over 3.4 million vehicles in the United States due to a fire risk. Both automakers...